Fredag 3 April | 11:40:40 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-11-10 08:00 Kvartalsrapport 2026-Q3
2026-07-23 08:00 Kvartalsrapport 2026-Q2
2026-05-19 N/A X-dag ordinarie utdelning GENO 0.00 SEK
2026-05-18 N/A Årsstämma
2026-04-28 08:00 Kvartalsrapport 2026-Q1
2026-02-12 - Bokslutskommuniké 2025
2025-11-07 - Kvartalsrapport 2025-Q3
2025-08-12 - Kvartalsrapport 2025-Q2
2025-05-22 - X-dag ordinarie utdelning GENO 0.00 SEK
2025-05-21 - Årsstämma
2025-05-21 - Kvartalsrapport 2025-Q1
2025-02-14 - Bokslutskommuniké 2024
2024-11-08 - Kvartalsrapport 2024-Q3
2024-08-20 - Kvartalsrapport 2024-Q2
2024-05-16 - X-dag ordinarie utdelning GENO 0.00 SEK
2024-05-15 - Kvartalsrapport 2024-Q1
2024-02-15 - Bokslutskommuniké 2023
2023-11-15 - Kvartalsrapport 2023-Q3
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-17 - X-dag ordinarie utdelning GENO 0.00 SEK
2023-05-16 - Årsstämma
2023-05-16 - Kvartalsrapport 2023-Q1
2023-02-15 - Bokslutskommuniké 2022
2022-11-15 - Kvartalsrapport 2022-Q3
2022-08-12 - Kvartalsrapport 2022-Q2
2022-05-13 - X-dag ordinarie utdelning GENO 0.00 SEK
2022-04-27 - Kvartalsrapport 2022-Q1
2022-02-08 - Bokslutskommuniké 2021
2021-11-12 - Kvartalsrapport 2021-Q3
2021-08-12 - Kvartalsrapport 2021-Q2
2021-05-21 - X-dag ordinarie utdelning GENO 0.00 SEK
2021-05-20 - Årsstämma
2021-04-29 - Kvartalsrapport 2021-Q1
2021-02-11 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-08-12 - Kvartalsrapport 2020-Q2
2020-05-06 - X-dag ordinarie utdelning GENO 0.00 SEK
2020-05-05 - Årsstämma
2020-04-29 - Kvartalsrapport 2020-Q1
2020-02-05 - Bokslutskommuniké 2019
2019-12-20 - Extra Bolagsstämma 2019
2019-11-21 - Kvartalsrapport 2019-Q3
2019-08-28 - Kvartalsrapport 2019-Q2
2019-05-24 - X-dag ordinarie utdelning GENO 0.00 SEK
2019-05-23 - Årsstämma
2019-05-08 - Kvartalsrapport 2019-Q1
2019-02-26 - Bokslutskommuniké 2018
2018-11-27 - Kvartalsrapport 2018-Q3
2018-08-28 - Kvartalsrapport 2018-Q2
2018-05-18 - X-dag ordinarie utdelning GENO 0.00 SEK
2018-05-17 - Årsstämma
2018-05-15 - Kvartalsrapport 2018-Q1
2018-02-28 - Bokslutskommuniké 2017
2017-11-27 - Kvartalsrapport 2017-Q3
2017-08-28 - Kvartalsrapport 2017-Q2
2017-05-12 - X-dag ordinarie utdelning GENO 0.00 SEK
2017-05-11 - Årsstämma
2017-05-08 - Kvartalsrapport 2017-Q1
2017-02-27 - Bokslutskommuniké 2016
2016-11-23 - Kvartalsrapport 2016-Q3
2016-08-29 - Kvartalsrapport 2016-Q2
2016-05-12 - Årsstämma
2016-05-06 - X-dag ordinarie utdelning GENO 0.00 SEK
2016-05-04 - Kvartalsrapport 2016-Q1
2016-02-15 - Bokslutskommuniké 2015
2015-11-23 - Kvartalsrapport 2015-Q3
2015-08-20 - Kvartalsrapport 2015-Q2
2015-05-11 - Kvartalsrapport 2015-Q1
2015-05-06 - X-dag ordinarie utdelning GENO 0.00 SEK
2015-05-05 - Årsstämma
2015-02-18 - Bokslutskommuniké 2014
2014-11-17 - Kvartalsrapport 2014-Q3
2014-08-25 - Kvartalsrapport 2014-Q2
2014-05-21 - X-dag ordinarie utdelning GENO 0.00 SEK
2014-05-20 - Årsstämma
2014-05-19 - Kvartalsrapport 2014-Q1
2014-02-27 - Bokslutskommuniké 2013
2013-11-28 - Kvartalsrapport 2013-Q3
2013-08-28 - Kvartalsrapport 2013-Q2
2013-04-26 - X-dag ordinarie utdelning GENO 0.00 SEK
2013-04-25 - Årsstämma
2013-04-24 - Kvartalsrapport 2013-Q1
2013-02-28 - Bokslutskommuniké 2012
2012-11-14 - Kvartalsrapport 2012-Q3
2012-08-29 - Kvartalsrapport 2012-Q2
2012-04-25 - Kvartalsrapport 2012-Q1
2012-04-04 - Split GENO 10:1
2012-03-21 - X-dag ordinarie utdelning GENO 0.00 SEK
2012-03-20 - Årsstämma
2012-02-16 - Bokslutskommuniké 2011
2011-11-10 - Kvartalsrapport 2011-Q3
2011-08-26 - Kvartalsrapport 2011-Q2
2011-07-21 - Extra Bolagsstämma 2011
2011-06-09 - Årsstämma
2011-04-29 - X-dag ordinarie utdelning GENO 0.00 SEK
2011-04-18 - Kvartalsrapport 2011-Q1
2011-02-15 - Bokslutskommuniké 2010
2010-11-05 - Kvartalsrapport 2010-Q3
2010-08-20 - Kvartalsrapport 2010-Q2
2010-05-18 - Kvartalsrapport 2010-Q1
2010-03-31 - X-dag ordinarie utdelning GENO 0.00 SEK
2010-03-30 - Årsstämma
2010-02-26 - Bokslutskommuniké 2009
2009-11-12 - Kvartalsrapport 2009-Q2
2009-10-08 - Kvartalsrapport 2009-Q3
2009-06-03 - X-dag ordinarie utdelning GENO 0.00 SEK
2009-06-02 - Årsstämma
2009-04-21 - Kvartalsrapport 2009-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Genovis är verksamt inom bioteknik. Störst inriktning återfinns mot utveckling av enzymer som används i diverse läkemedel. Bolagets patenterade NIMT teknologi är utvecklad för att underlätta för LifeScience industrin att bedriva preklinisk forskning. Bolagets produkter vidaresäljs under ett flertal varumärken. Genovis etablerades 1999 och har sitt huvudkontor i Lund.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-03-31 09:00:00

Genovis AB today announces the commercial launch of SEQguard™ Dino Preserve, an RNA preservation product tested and optimized for Plasmidsaurus, a leading Sequencing as a Service company. The product enables researchers to ship extracted RNA samples at ambient temperatures, eliminating the need for dry ice or cold-chain logistics and making high-quality RNA sequencing more accessible, cost-efficient, and sustainable.

Maintaining RNA integrity during transport has historically required cold-chain logistics involving dry ice or liquid nitrogen — adding cost, logistical complexity, and environmental burden to RNA sequencing workflows. SEQguard™ Dino Preserve addresses this challenge directly, allowing researchers to ship extracted RNA at ambient temperatures without compromising sequencing yield and quality. The product has been validated for seamless integration with Plasmidsaurus’ high-throughput sequencing infrastructure and ultrafast-turnaround service.

The solution delivers a compelling combination of customer benefits: researchers can ship RNA samples reliably at ambient temperatures, significantly reducing shipping costs compared to dry ice logistics while substantially lowering the carbon footprint associated with cold-chain transport. By removing dependency on frozen shipping, SEQguard™ Dino Preserve simplifies sample preparation and gives researchers peace of mind that their samples will arrive intact and sequencing-ready, even over extended shipping times and across distances and climates.

Developed through close collaboration between Genovis’ and Plasmidsaurus’ teams, this innovation is specifically tailored for Plasmidsaurus customers and optimized to integrate seamlessly with their sequencing workflows. It enables consistent, high-quality gene expression profiling from RNA samples shipped globally at ambient temperature. The product is available immediately to Plasmidsaurus’ customers working in RNA sequencing.

“By partnering with Genovis to bring SEQguard™ Dino Preserve into the Plasmidsaurus ecosystem, we’re making high-quality RNA-seq as simple and reliable as dropping off a tube at a local drop box. Together, we eliminate the logistical headache so customers can focus on their science, not shipping — unlocking unprecedented simplicity for ultrafast, high-quality gene expression data,” said Mark Budde, CEO and co-founder of Plasmidsaurus.

“The launch of SEQguard™ Dino Preserve is a strong example of how we are expanding the commercial application of our SEQURNA technology platform,” said Fredrik Olsson, CEO at Genovis. “Powered by the SEQURNA team’s expertise and innovation, this purpose-built solution tackles a persistent challenge in sequencing logistics — delivering speed, cost savings and a meaningfully smaller carbon footprint. This demonstrates both the breadth of our technology platform and our ability to create tangible value for researchers.”

RNA sequencing is among the fastest-growing areas of molecular biology and drug development, driven by advances in transcriptomics, multiomics, single-cell analysis, and target discovery. As throughput increases and sequencing costs decline, sample logistics and workflow efficiency are increasingly important factors in making RNA-seq services globally accessible.

More about SEQguard™ Dino Preserve

ABOUT PLASMIDSAURUS
Plasmidsaurus is on a mission to accelerate science with the best sequencing. The company’s sequencing services, spanning whole plasmids, RNA-seq, amplicons, whole genomes, and microbiomes, are used daily by thousands of innovators, including Nobel Prize winners, dynamic biotech startups, pharmaceutical companies, research labs, and DIY biohackers. Plasmidsaurus’s global network of labs operates day and night to enable world-changing discoveries. For more, visit: plasmidsaurus.com